Chardan Healthcare Acquisition 2 Corp. (CHAQ): Price and Financial Metrics


Chardan Healthcare Acquisition 2 Corp. (CHAQ): $8.41

-0.95 (-10.15%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CHAQ Stock Price Chart Interactive Chart >

Price chart for CHAQ

CHAQ Price/Volume Stats

Current price $8.41 52-week high $11.12
Prev. close $9.36 52-week low $8.06
Day low $8.06 Volume 242,600
Day high $9.35 Avg. volume 55,653
50-day MA $9.95 Dividend yield N/A
200-day MA $10.10 Market Cap 90.64M

Chardan Healthcare Acquisition 2 Corp. (CHAQ) Company Bio


Chardan Healthcare Acquisition 2 Corp. intends to acquire assets and businesses through a merger, share exchange, stock purchase, recapitalization, reorganization, or other similar business combination. The company was founded in 2018 and is based in New York, New York.


CHAQ Latest News Stream


Event/Time News Detail
Loading, please wait...

CHAQ Latest Social Stream


Loading social stream, please wait...

View Full CHAQ Social Stream

Latest CHAQ News From Around the Web

Below are the latest news stories about Chardan Healthcare Acquisition 2 Corp that investors may wish to consider to help them evaluate CHAQ as an investment opportunity.

Chardan Healthcare Acquisition 2 Corp. Announces Stockholder Approval Of Business Combination With Renovacor, Inc.

Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) ("CHAQ"), a special purpose acquisition company sponsored by Chardan Capital Markets ("Chardan"), today announced the results for the proposals considered and voted upon by its stockholders at its special meeting held on September 1, 2021 (the "Special Meeting"), regarding the proposed business combination with Renovacor, Inc. ("Renovacor"), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for de

Yahoo | September 1, 2021

Chardan Healthcare Acquisition 2 Corp. Announces Renovacor's Appointment of Matt Killeen, Ph.D., as Chief Scientific Officer

Renovacor, Inc. ("Renovacor"), an early–stage biotechnology company developing adeno-associated virus (AAV)–based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Matt Killeen, Ph.D., as chief scientific officer (CSO), effective as of September 1, 2021. Chardan Healthcare Acquisition 2 Corp. (CHAQ) previously announced on March 23, 2021 that it entered into a definitive merger agreement with Re

Yahoo | August 25, 2021

Chardan Healthcare Acquisition 2 Corp. Announces Record Date for Stockholders Eligible to Vote on Merger

PHILADELPHIA and NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Chardan Healthcare Acquisition 2 Corp. (the "Company") announced that the close of business on Thursday, August 5, 2021, has been set as the record date for the determination of stockholders eligible to receive the proxy and vote at

PR Newswire | August 3, 2021

Renovacor Announces the Appointment of Elizabeth White, Ph.D., as Chief Business Officer and Senior Vice President of Operations

Dr. White is an industry leader with over three decades of pharmaceutical experience in business management and strategy with a focus on rare diseases and gene therapiesPHILADELPHIA, July 19, 2021 (GLOBE NEWSWIRE) -- Renovacor, Inc. (“Renovacor”), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Elizabeth (Beth)

Yahoo | July 19, 2021

Renovacor Announces the Appointment of Jiwen Zhang, Ph.D., as Senior Vice President, Regulatory Affairs and Quality Assurance

Dr. Zhang has over 20 years of experience in regulatory affairs, with over a decade specifically in the field of cell and gene therapyPHILADELPHIA, July 12, 2021 (GLOBE NEWSWIRE) -- Renovacor, Inc. (“Renovacor”), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Jiwen Zhang, Ph.D., as senior vice president, regula

Yahoo | July 12, 2021

Read More 'CHAQ' Stories Here

CHAQ Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2021 0.00%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.654 seconds.